Visual Performance of Soft Contact Lenses With Myopia Control Optics
NCT ID: NCT05141448
Last Updated: 2025-04-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
79 participants
INTERVENTIONAL
2021-11-22
2022-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Accommodative Responses of Soft Contact Lenses for Myopia Control
NCT03635528
Evaluating Visual Acuity and Initial Fit Performance of Two Soft Contact Lenses
NCT04954833
Myopia Progression After Ceasing Myopia Control Contact Lens Wear
NCT01829230
Evaluating ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management
NCT05634408
Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist
NCT02024698
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test1/Test2/Control
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test1/Test2/Control.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Test1/Control/Test2
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test1/Control/Test2.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Test2/Test1/Control
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test2/Test1/Control.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Test2/Control /Test1
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Test2/Control /Test1.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Control/Test1/Test2
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Control/Test1/Test2.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Control/Test2/Test1
Eligible subjects will be fitted with the run-in lens for approximately one week, then randomized to the sequence Control/Test2/Test1.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1-Day Acuvue Moist
Run-in Contact Lens
EMO-118
Test Lens1
EMO-114
Test Lens2
MiSight® 1 day
Control Lens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Read (or be read to) and sign the CHILDREN'S ASSENT (Information and Assent Form) and receive a fully executed copy of the form.
2. Have parents or legal guardians who must read, understand, and sign the STATEMENT OF INFORMED CONSENT (Parental Permission Form and Authorization to Use and Disclose Medical Information).
3. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
4. Be between 7 and 17 (inclusive) years of age at the time of screening.
5. By self-report, habitually wear soft contact lenses or be a current non-contact lens wearer interested in soft lens wear.
6. The non-vertex corrected best sphere distance refraction must be between -1.00 D and -4.50 D (inclusive) in each eye.
7. The magnitude of the cylindrical component of the subject's vertex-corrected distance refraction must be less than or equal to 0.75 D (inclusive) in each eye with any degree of axis.
8. The distance visual acuity with best sphere distance correction must be 20/25 or better in each eye.
9. Have ≤ 1.50 D difference in subjective best-sphere refraction between the two eyes.
10. Have 20/40 or better vision in each eye with wearable spectacles or uncorrected.
Exclusion Criteria
1. Be currently pregnant or lactating.
2. Be diabetic.
3. Be currently using any ocular medications. Lubricants (artificial tears) eyedrops are allowed.
4. Have any current ocular infection of any type.
5. Have any systemic disease (e.g., Sjogren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g., rheumatoid arthritis), any underlying medical condition that makes subjects at risk of severe COVID complications, a history of serious mental illness or seizures, or other diseases, by parent or legal guardian's self-report, which are known to interfere with contact lens wear and/or participation in the study.
6. Use of systemic medication (e.g., chronic steroid use) that are known to interfere with contact lens wear and/or participation in the study. See section 9.1 for additional details regarding excluded systemic medications.
7. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 30 days.
8. Be currently wearing lenses in an extended wear modality.
9. Be currently wearing soft contact lenses for astigmatism in either eye.
10. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.
11. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
12. Children who are wards of the State or any other agency, institution, or entity.
13. Have any ocular allergies, infections, or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but is not limited to, entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis.
14. Have grade 3 or greater palpebral conjunctival observations or any other grade 2 slit lamp findings on the ISO 11980 classification scale.
15. Have strabismus (intermittent or constant) or amblyopia.
16. Have a history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar).
17. Have any central corneal scar.
18. Have a pupil diameter under bright illumination of less than 2 mm in either eye.
7 Years
17 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vision Optique
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-6457
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.